{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-032533","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2025-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.527179+00:00","generated_at":"2026-05-17T10:09:35.605337+00:00","sec_items":["3.02"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Opus Genetics raises $3.5M in private placement led by board chair for gene therapy manufacturing","bullets":["Issued 3,138,338 shares at ~$1.11/sh in private placement; gross proceeds $3.5M.","Led by board chair Cam Gallagher ($1M) and lead independent director Sean Ainsworth.","Proceeds to expedite manufacturing process development for gene therapy candidates OPGx-LCA5 and OPGx-BEST1.","Private placement closed August 25, 2025; exempt under Section 4(a)(2) and Regulation D."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-032533","json":"https://secwatch.observer/filing/0001140361-25-032533.json","markdown":"https://secwatch.observer/filing/0001140361-25-032533.md","text":"https://secwatch.observer/filing/0001140361-25-032533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125032533/0001140361-25-032533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125032533/ef20054479_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:09:35.605337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}